Alexa Freedman, PhD, is an epidemiologist at the Northwestern University Feinberg School of Medicine.

Men at Risk of Coronary Heart Disease Development 10 Years Before Women, With Alexa Freedman, PhD

An analysis of historical data from the Coronary Artery Risk Development in Young Adults (CARDIA) study has suggested that men develop 

Sex-specific differences in cardiovascular disease have long been attributed to a variety of pathways, including hormonal influences, variations in cardiovascular health behaviors and factors, and exposure to adverse social determinants of health. Men historically have higher rates of smoking, 

 – however, recent population shifts have resulted in similar rates among women. These shifts warrant a reexamination of existing data.

“One of the things we noted in our study was that men are much less likely to receive preventive care in young adulthood,” Alexa Freedman, PhD, an epidemiologist in the department of preventive medicine at Northwestern University Feinberg School of Medicine, told 

 in an exclusive interview. “This might be an opportunity to enhance cardiovascular disease screening and prevention efforts in young men, as we see that risk starting to emerge earlier.”

CARDIA was a prospective cohort study which recruited 5115 Black and White participants between 18-30 years from March 1985 to June 1986. During the trial, health measures and surveys were collected at baseline, after which point patients completed examinations at study years 2, 5, 7, 10, 15, 20, and 30. Retention rates among surviving patients at each examination period were 91%, 86%, 81%, 79%, 74%, 72%, 72%, and 71%, respectively.

CARDIA investigators defined incident cardiovascular disease as fatal or nonfatal myocardial infarction, 

, coronary revascularization, or carotid or peripheral arterial disease, among other conditions. Cardiovascular disease was also categorized into 3 subtypes – CHD, stroke, and heart failure. Cardiovascular disease events were determined at each visit and via annual contacts, during which participants reported any hospital admissions and outpatient procedures.

For the purpose of this analysis, Freedman and colleagues evaluated 7 health behaviors and factors representing cardiovascular health. Behaviors included diet, physical activity, and smoking status – diet was assessed at baseline and years 7 and 20 via a questionnaire on dietary intake, while physical activity was determined based on frequency of participation in 13 moderate- and vigorous-intensity activities over the previous 12 months, and smoking status was determined via a questionnaire.

Health factors investigated included body mass index (BMI), blood pressure, blood lipids, and blood glucose. BMI was calculated based on height in cm and weight in kg, measured at each visit. Blood pressure was measured in triplicate at each examination. Fasting lipids were determined via ethylene-diaminetetraacetic acid plasma at each examination, while fasting serum glucose was assessed with the hexokinase ultraviolet method at baseline.

Of the 5112 patients included in the analysis, 2785 were women and 2327 were men. Mean age at baseline was 24.9 years (standard deviation [SD], 3.7) for women and 24.8 (SD, 3.6) for men. Over a median follow-up period of 34.1 years, there were 387 cardiovascular disease events – 160 among women and 227 among men.

By the end of the analysis, investigators had noted significant differences between cumulative incidence for premature total cardiovascular disease among men and women. Men achieved cumulative incidence of 5% earlier than women by 7 years (

 <.001); by age 50, the cumulative incidence was 4.7% among men and 2.9% among women. CHD was the most common form of cardiovascular disease, and male patients also reached cumulative incidence of CHD of 2% earlier than women by 10.1 years (

 <.001), with a cumulative incidence of 2.5% by age 50 in men versus 0.9% among women.

“One of the things I’ll note is that heart failure and stroke tend to develop later in life,” Freedman said. “We were looking at a sample where all participants were under 65 at the latest observation period, so we weren’t necessarily able to see those differences because we just didn’t have enough premature events in that sense. Those sex differences could emerge later in life.”

Editor’s Note: Freedman reports no relevant disclosures.

Wiley. Do men develop cardiovascular disease earlier than women? 

. January 28, 2026. Accessed January 30, 2026. 

https://www.eurekalert.org/news-releases/1113905

Freedman AA, Colangelo LA, Ning H, et al. Sex differences in age of onset of premature cardiovascular disease and subtypes: The coronary artery risk development in young adults study. Journal of the American Heart Association. Published online January 28, 2026. 

Videos

Freedman discusses a new analysis of the CARDIA study that indicates male patients’ greater risk of CHD at younger ages.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Giles W. Story, PhD, from the University College London

 Delay Discounting vs Traditional Predictors of MDD Relapse, With Giles Story, PhD

New evidence suggests that delay discounting, which is linked to depression and serotonin function, offers little predictive value for identifying patients at risk of relapse after stopping antidepressant treatment. While delay discounting was elevated in remitted 

and correlated with residual depressive symptoms, it neither changed following antidepressant discontinuation nor predicted relapse over 6 months of follow-up.

“We know that people with a history of depression tend to be more impatient for rewards,” Giles W. Story, PhD, from the University College London, told 

 “And then secondly, [there is] the…separate line of evidence that links depression to changes in serotonin function.”

Giles said the most reliable evidence comes from animal studies showing that serotonergic injections cause animals to be more impatient to get rewards. He predicted that delay discounting could reflect vulnerability to future depression and predict relapse, with greater baseline impatience associated with a greater likelihood of relapse. He also predicted that delay discounting might be a marker of discontinuation.

“In broad brush terms, the idea here is that some people who stop their antidepressants might experience a reduction in serotonin,” Story said.

In a multi-site longitudinal study, investigators examined whether delay discounting, a behavioral measure of impatience for future rewards, could predict relapse after stopping antidepressant medication in patients with remitted MDD. The study, led by Doron Elad, PhD, from Technion-Israel Institute of Technology, and Giles W. Story, PhD, enrolled 97 patients with remitted MDD receiving antidepressant medication (77% female; average age, 34.78 years) and 54 matched healthy controls (70% female; average age, 33.52 years). The study included participants from both Zurich (MDD: 71; controls: 32) and Berlin (MDD: 26; controls: 22).

Using 2 validated delay discounting tasks, investigators measured participants’ preference for immediate versus delayed monetary rewards, with steeper discounting indicating more impatience to wait for symptom improvement. Patients were assessed before and after discontinuation and followed for 6 months to track relapse.

Story explained that delay discounting provides a snapshot of how individuals value the future, offering a behavioral marker that differs conceptually from traditional clinical predictors such as the number of prior episodes or residual symptoms.

“You can think of it as a way [of capturing a] particular point in time somebody's making decisions,” Story said. “In some ways, you could say that's more objective. It's harder to second-guess.”

At baseline, patients with remitted MDD demonstrated significantly steeper discounting than healthy controls (Cohen’s d = 0.34), indicating reduced willingness to wait for future rewards. For example, patients were willing to accept approximately €66 immediately instead of €75 after several weeks, compared with €70 among controls. Baseline discounting was also modestly correlated with depressive symptom severity, even below the clinical threshold for relapse.

Contrary to the study’s primary hypotheses, neither baseline discounting nor early changes following antidepressant discontinuation predicted subsequent relapse. Discontinuation itself did not significantly alter discounting behavior, despite measurable increases in depressive symptoms among those who stopped medication earlier.

The findings suggest that while delay discounting is elevated in remitted depression and reflects residual symptom burden, it does not function as a clinically meaningful predictor of relapse after antidepressant discontinuation.

Elad D, Story GW, Berwian IM, Stephan KE, Walter H, Huys QJM. Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation. 

Although patients with remitted MDD showed greater impulsivity than controls, a study found no link between delay discounting and relapse risk after stopping antidepressants.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Delay Discounting vs Traditional Predictors of MDD Relapse, With Giles Story, PhD

Holly Kramer, MD, is a nephrologist at Loyola University Medical Center and the editor in chief of 

Vlado Perkovic is Dean and Scientia Professor of Medicine at UNSW Sydney. He is also a Professorial Fellow at The George Institute and a Staff Specialist in Nephrology at the Royal North Shore Hospital in Sydney.

 continue to rise as global clinical challenges, the intersection between excess weight and kidney function has become increasingly important to patient outcomes and disease progression.

To discuss the association between excess adiposity, defined as a body mass index (BMI) ≥30 kg/m², and impaired renal function, HCPLive spoke with 2 experts in nephrology to glean insights relevant to clinical practice.

Each kidney contains a finite number of nephrons, ranging from approximately 200,000 to 2 million per kidney. As body mass increases, metabolic demand rises, prompting compensatory increases in glomerular capillary pressure, intraglomerular flow, and single-nephron glomerular filtration. Over time, this sustained hyperfiltration places mechanical stress on the glomerulus, contributing to podocyte injury, glomerulosclerosis, proteinuria, and progressive nephron loss. Obesity itself has been independently linked to these pathophysiological changes, even after accounting for common comorbidities such as diabetes and hypertension.

This physiologic strain becomes more pronounced at increased levels of adiposity, where 

obesity may contribute directly to renal injury

“Severe obesity, like a BMI above 40, can also lead to nephron loss itself because of the inflammatory effects obesity has on the body,” explained Holly Kramer, MD, a nephrologist at Loyola University Medical Center and editor in chief of 

The inflammatory burden associated with severe obesity may help explain why individuals with higher BMI often experience more rapid CKD progression, even in the absence of advanced disease at baseline.

Clinical trial populations have also highlighted the frequent coexistence of impaired kidney function and elevated BMI. Vlado Perkovic, MBBS, PhD, the provost at the University of New South Wales and an investigator in the FLOW trial, has observed this pattern firsthand.

FLOW, which evaluated kidney outcomes in adults with type 2 diabetes (T2D) and CKD, was not designed as a weight-loss study and did not include BMI-based eligibility criteria. Participants were enrolled based on kidney disease parameters, including an estimated glomerular filtration rate (eGFR) of 25–75 mL/min/1.73 m² and a urine albumin-to-creatinine ratio (UACR) of >300–<5000 mg/g, or 100–5000 mg/g among those with an eGFR of 25–<50 mL/min/1.73 m². Notably, a quarter of patients had a BMI <27 in the FLOW trial.

Despite this, the mean BMI of participants in the FLOW trial was 32. Similarly, the CREDENCE trial, which also did not focus on weight loss, reported an average BMI of 31. This highlights obesity as a prevalent, rather than incidental, comorbidity in contemporary CKD populations. Taken together, these findings underscore the importance of considering body weight as a core component of CKD risk assessment, rather than a secondary concern.

“What that tells us is that people with diabetes and kidney disease, on average, are very overweight,” said Perkovic. “And certainly are likely to benefit from weight loss as well. These are wonderful treatments that help address multiple sorts of parallel pathologies that are developing in many of our patients, and it's exciting to think about the future and whether some of the more potent agents that produce even more weight loss might.”

 Utilizing diet to prevent obesity, preserve kidney function, with Holly Kramer, MD. 

https://www.hcplive.com/view/utilizing-diet-prevent-obesity-preserve-kidney-function-holly-kramer-md

Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. 

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. 

Podcasts

Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

 Obesity’s Double Role in CKD as Comorbidity and Driver

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include new phase 2 data on CT-388 for obesity, the US Food and Drug Administration (FDA) approval of a labeling supplement permitting repeat administration of travoprost intracameral implant (iDose TR) in open-angle glaucoma or ocular hypertension, new American Society of Hematology (ASH) guidelines on light chain (AL) amyloidosis, the FDA approval of carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi) for presbyopia, and the US Centers for Medicare & Medicaid Services selection of 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first-ever Part B drugs.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of January 25, 2026—let’s jump in!

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

On January 27, 2026, Genentech, a member of the Roche Group, announced positive topline results from CT388-103, a phase 2 clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity.

Results showed once-weekly subcutaneous injections of CT-388 titrated up to 24 mg resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. A clear dose-response relationship on the weight loss was also observed.

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

On January 28, 2026, the FDA approved a labeling supplement permitting repeat administration of travoprost intracameral implant (iDose TR) for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The update modifies prior labeling that limited use to a single administration and is based on accumulated clinical safety data, including corneal endothelial outcomes, submitted by the manufacturer.

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

On January 28, 2026, ASH published new clinical practice guidelines aimed at improving the early, timely, and accurate diagnosis of AL amyloidosis. The document, published in 

, outlines best practices to support clinicians in recognizing and diagnosing AL amyloidosis, a disease frequently missed or diagnosed late due to its heterogeneous presentation.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

On January 28, 2026, the FDA approved Tenpoint Therapeutics’ carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi) for the treatment of presbyopia in adults, representing the first regulatory authorization of a fixed-dose, dual-agent topical therapy for age-related near vision degradation.

CMS Selects 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program

On January 27, 2026, the US Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B for the third cycle of the Medicare Drug Price Negotiation Program. CMS additionally selected 1 previously negotiated drug, linagliptin (Tradjenta), for the program’s first renegotiations. Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028.

Articles

Genentech's phase 2 trial of CT-388 for obesity demonstrated significant weight loss without plateauing at 48 weeks. The FDA approved a labeling update for iDose TR, allowing repeat administration for open-angle glaucoma and ocular hypertension. ASH released new guidelines for diagnosing AL amyloidosis to improve early detection. The FDA approved Yuvezzi, the first dual-agent eye drop for presbyopia. CMS selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including Part B drugs, with negotiations set for 2026 and prices effective in 2028.

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

Hematology

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 01/25

Pre-Symptomatic Detection of Crohn’s Disease Through Flagellin Antibodies, With Sun-Ho Lee, MD, PhD

Crohn’s disease is typically diagnosed only after patients develop overt gastrointestinal symptoms, yet mounting evidence suggests that the pathogenic process begins years earlier.

During this silent, preclinical phase, immune dysregulation and host-microbe interactions may already be driving disease evolution. Understanding these earliest events has become a key priority in inflammatory bowel disease research, with the goal of identifying biomarkers that can predict risk, inform surveillance, and ultimately enable strategies to delay or prevent disease onset.

A new study from the Lunenfeld-Tanenbaum Research Institute and Mount Sinai Hospital’s Center for Inflammatory Bowel Disease has identified a blood test that can predict Crohn’s disease years before symptoms appear by measuring a person’s immune response to flagellin.

“Up until this study, it was unclear, especially in healthy first relatives, what type of flagellin antigens were the drivers or triggered the immune response, and if these antibody responses were associated with other biomarkers that are related to onset of Crohn's,” study investigator Sun Ho Lee, MD, PhD, a gastroenterologist at Sinai Health Zane Cohen Centre for Digestive Diseases, told 

Seeking to address that gap and build upon previous research regarding immune response against gut microbes prior to Crohn’s diagnosis, he and a team of investigators followed 381 first-degree relatives of Crohn’s patients as part of the Genetic, Environmental, and Microbial (GEM) Project, a global cohort of > 5000 healthy first-degree relatives of people with Crohn’s disease. Among the population in the present study, 77 went on to develop the disease.

Using 2 complementary assays, the researchers evaluated antibody responses to 49 recombinant flagellin antigens. Results showed 19 of 49 IgG antimicrobial antibody responses were significantly associated with the risk of Crohn’s. These antibodies were reactive to the Lachnospiraceae family, particularly Roseburia-derived flagellins.

Additionally, 5 antibodies positively correlated with fecal calprotectin, whereas 3 positively correlated with lactulose-to-mannitol ratio. Of note, these IgG-seroreactive flagellins shared significant amino acid sequence homology, characterized by a conserved "hinge peptide" within D0-D1 domains of the amino-terminus. The cytometric bead array confirmed that elevated IgG seroreactivity to the hinge peptide is associated with future risk of Crohn’s, independent of both lactulose-to-mannitol ratio and fecal calprotectin.

Taken together, Lee emphasized that these findings help refine the understanding of preclinical Crohn’s disease and narrow the focus to specific microbial antigens and epitopes. He suggested that such highly specific immune signatures could form the basis for future biomarkers aimed at identifying individuals at risk of Crohn’s before clinical symptoms emerge.

Editors’ Note: Lee reports no relevant disclosures.

Wu RY, Xue M, Zhao Q, et al. Serum IgG Response to a Conserved Domain of Commensal Flagellins Predicts Future Risk of Crohn's Disease in First-degree Relatives. 

Lunenfeld-Tanenbaum Research Institute. A simple blood test can predict Crohn’s disease years before symptoms appear. EurekAlert! 

https://www.eurekalert.org/news-releases/1111855

Lee explains what is known about the preclinical phase of Crohn’s disease before symptoms appear and describes his study on the role immune dysregulation plays.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Gianluca Florineth, MSc, from the Translational Research Center, University Hospital of Psychiatry and Psychotherapy at the University of Bern in Switzerland.

Meta-analysis links longer preparation therapy and follow-up duration to depressive symptom change in psilocybin- and LSD-assisted treatment. 

Preparation Improves Psychedelic Therapy for MDD, With Gianluca Florineth, MSc

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

OptIMMize-1: New Efficacy and Safety Data on Risankizumab in Pediatric Psoriasis

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

In this segment, Nancy Reau, MD, and Kimberly Brown, MD, discuss ongoing challenges with viral hepatitis elimination efforts and clinical shortcomings in screening.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Identifying the Missing Link in Viral Hepatitis Elimination Efforts

Hiroshi Iwamoto, MD, PhD, from Hiroshima University

New data suggest asthma-related depression may be biologically distinct from MDD, with greater serum BDNF tied to worse disease severity and lower physical activity.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Elevated BDNF Linked to Depressive Symptoms in Patients with Asthma, With Hiroshi Iwamoto, MD, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Prevalence in US Increasing Drastically, Expected to Continue into 2035

Clinicians can provide dietitian intervention to reduce the risk of obesity, which is independently associated with CKD.  


Utilizing Diet to Prevent Obesity, Preserve Kidney Function, With Holly Kramer, MD

Sina Kianersi, PhD, is a research fellow in medicine at Brigham and Women’s Hospital.

Kianersi discusses how, although evening chronotype can be associated indirectly with increased CVD risk, this can be mediated via Life’s Essential 8 scores.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Staying Up Late Associated With CVD Risk Through Worse LE8 Scores, With Sina Kianersi, PhD

At the Maui Derm Hawaii 2026 conference, Lawrence Eichenfield, MD, spoke about highlights from his talk, ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Highlighting Therapeutic Updates for Atopic Dermatitis and Itch, With Lawrence Eichenfield, MD

The safety and efficacy of risankizumab versus deucravacitinib were evaluated among patients with moderate psoriasis and no prior biologic use.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Centers for Medicare & Medicaid Services selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first-ever Part B drugs.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Latest News

Men at Risk of Coronary Heart Disease Development 10 Years Before Women, With Alexa Freedman, PhD

Delay Discounting vs Traditional Predictors of MDD Relapse, With Giles Story, PhD

Obesity’s Double Role in CKD as Comorbidity and Driver

The HCPFive: Top News for Healthcare Providers from the Week of 01/25

Pre-Symptomatic Detection of Crohn’s Disease Through Flagellin Antibodies, With Sun-Ho Lee, MD, PhD